Prostate cancer mortality reduction by prostate-specific antigen–based screening adjusted for nonattendance and contamination in the European Randomised Study …
BACKGROUND: Prostate-specific antigen (PSA) based screening for prostate cancer (PCa)
has been shown to reduce prostate specific mortality by 20% in an intention to screen (ITS) …
has been shown to reduce prostate specific mortality by 20% in an intention to screen (ITS) …
Prostate-specific antigen–based prostate Cancer screening: reduction of prostate cancer mortality after correction for nonattendance and contamination in the …
LP Bokhorst, CH Bangma, GJLH van Leenders… - European urology, 2014 - Elsevier
Background Large randomized screening trials provide an estimation of the effect of
screening at a population-based level. The effect of screening for individuals, however, is …
screening at a population-based level. The effect of screening for individuals, however, is …
A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer
J Hugosson, MJ Roobol, M Månsson, TLJ Tammela… - European urology, 2019 - Elsevier
Abstract Background The European Randomized study of Screening for Prostate Cancer
(ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening …
(ERSPC) has previously demonstrated that prostate-specific antigen (PSA) screening …
Prostate cancer mortality in the Finnish randomized screening trial
TP Kilpeläinen, TL Tammela, N Malila… - Journal of the …, 2013 - academic.oup.com
Background Prostate cancer (PC) screening with prostate-specific antigen (PSA) has been
shown to decrease PC mortality by the European Randomized Study of Screening for …
shown to decrease PC mortality by the European Randomized Study of Screening for …
Screening for prostate cancer: results of the Rotterdam section of the European randomized study of screening for prostate cancer
MJ Roobol, R Kranse, CH Bangma, AG van Leenders… - European urology, 2013 - Elsevier
Background Evidence from randomized trials on the effects of screening for prostate cancer
(PCa) on disease-specific mortality accumulates slowly with increasing follow-up. Objective …
(PCa) on disease-specific mortality accumulates slowly with increasing follow-up. Objective …
Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit
PJ Van Leeuwen, D Connolly, A Gavin… - European Journal of …, 2010 - Elsevier
BACKGROUND: To estimate the benefits of prostate-specific antigen (PSA) screening on
prostate cancer (Pca) metastasis and Pca-specific mortality, we compared two populations …
prostate cancer (Pca) metastasis and Pca-specific mortality, we compared two populations …
Screening and prostate-cancer mortality in a randomized European study
FH Schröder, J Hugosson, MJ Roobol… - New England journal …, 2009 - Mass Medical Soc
Background The European Randomized Study of Screening for Prostate Cancer was
initiated in the early 1990s to evaluate the effect of screening with prostate-specific–antigen …
initiated in the early 1990s to evaluate the effect of screening with prostate-specific–antigen …
Prostate cancer screening with prostate-specific antigen (PSA) test: a systematic review and meta-analysis
Objective To investigate the efficacy and safety of prostate-specific antigen (PSA) testing to
screen for prostate cancer. Design Systematic review and meta-analysis. Data sources …
screen for prostate cancer. Design Systematic review and meta-analysis. Data sources …
Prostate-cancer mortality at 11 years of follow-up
FH Schröder, J Hugosson, MJ Roobol… - … England Journal of …, 2012 - Mass Medical Soc
Background Several trials evaluating the effect of prostate-specific antigen (PSA) testing on
prostate-cancer mortality have shown conflicting results. We updated prostate-cancer …
prostate-cancer mortality have shown conflicting results. We updated prostate-cancer …
Effect of a low-intensity PSA-based screening intervention on prostate cancer mortality: the CAP randomized clinical trial
Importance Prostate cancer screening remains controversial because potential mortality or
quality-of-life benefits may be outweighed by harms from overdetection and overtreatment …
quality-of-life benefits may be outweighed by harms from overdetection and overtreatment …